Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Oncology and therapy - 12(2024), 1 vom: 14. Feb., Seite 13-17 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ko, Heidi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Editorial |
|---|
| Anmerkungen: |
Date Revised 24.02.2024 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s40487-023-00249-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364544619 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364544619 | ||
| 003 | DE-627 | ||
| 005 | 20240229145751.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40487-023-00249-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1304.xml |
| 035 | |a (DE-627)NLM364544619 | ||
| 035 | |a (NLM)37962832 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ko, Heidi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a HER2 testing | |
| 650 | 4 | |a HER2-directed antibody–drug conjugate | |
| 650 | 4 | |a HER2-low | |
| 650 | 4 | |a Metastatic breast cancer | |
| 700 | 1 | |a Previs, Rebecca A |e verfasserin |4 aut | |
| 700 | 1 | |a Strickland, Kyle C |e verfasserin |4 aut | |
| 700 | 1 | |a Klein, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Caveney, Brian |e verfasserin |4 aut | |
| 700 | 1 | |a Chiruzzi, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Eisenberg, Marcia |e verfasserin |4 aut | |
| 700 | 1 | |a Severson, Eric A |e verfasserin |4 aut | |
| 700 | 1 | |a Ramkissoon, Shakti |e verfasserin |4 aut | |
| 700 | 1 | |a Saini, Kamal S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncology and therapy |d 2016 |g 12(2024), 1 vom: 14. Feb., Seite 13-17 |w (DE-627)NLM269530347 |x 2366-1089 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2024 |g number:1 |g day:14 |g month:02 |g pages:13-17 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40487-023-00249-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2024 |e 1 |b 14 |c 02 |h 13-17 | ||